Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2006

View Archived Issues

Study data reveal analgesic profile of tapentadol

RN-624 relieves pain from knee osteoarthritis

Hm-E16: potential monoclonal antibody treatment for neuro-invasive WNV

Merck Sharp and Dohme presents novel NK-1R antagonists

MARINA reveals ranibizumab safety, quality of life impact in macular degeneration

DNA repair seen in reconstructed skin with liposome-encapsulated T4 endonuclease V

Lenalidomide effective in cutaneous T-cell lymphoma: preliminary phase II results

AstraZeneca rounds up recent developments

Medivir presents summary of quarterly activities

CHI-033: a new selective inhibitor of Coxsackie B viral replication

Rac1 GTPase a novel antiplatelet target for the management of thrombosis

YM Biosciences completes Eximias acquisition

Advexin p53 therapy shows utility for Li-Fraumeni syndrome

CYT-500 cleared for first U.S. phase I study

Trial studies SIR-Spheres with Xeloda for metastatic liver cancer

Bionovo advancing MF-101 for vasomotor symptoms

Chelsea Therapeutics begins development program for droxidopa

Ube Industries and Santen to jointly develop ROCK inhibitor DE-104

Quigley begins clinical testing of QR-333 in diabetic peripheral neuropathy

Merck & Co. to acquire GlycoFi and Abmaxis

Aradigm awarded orphan drug status for liposomal ciprofloxacin in cystic fibrosis

Immunomedics and UCB sign agreement for epratuzumab

Kissei signs agreement for anti-CD20 humanized monoclonal antibody

Otsuka launches Ozex Ophthalmic solution in Japan

Phase I results for AnGes' HGF genetic agent for ischemic heart disease

Yasminelle completes European mutual recognition procedure

Novel treatment options described for disorders of impaired metabolism

Urief launched in Japan for urinary disturbance associated with enlarged prostate

Novel antiinfective agents disclosed in recent patent literature

New therapeutic agents for asthma, COPD, etc. reported in recent patent literature

Preclinical data on novel HIF prolyl hydroxylase inhibitor reported by FibroGen

Novel antipsoriatic demonstrates efficacy in vivo

Senju reports positive preclinical data on the calpain inhibitor SNJ-1945

Bortezomib may be useful to treat retinoblastoma

Synthesis and characterization of novel dipeptidyl peptidase IV inhibitors from Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...